论文部分内容阅读
目的:观察川芎嗪联合阿托伐他汀治疗肺动脉高压的临床疗效及安全性。方法:将96例肺动脉高压患者随机分成两组,其中治疗组48人,对照组48人。治疗组患者在常规治疗基础上采川芎嗪联合阿托伐他汀治疗,对照组患者在常规治疗基础上单采用阿托伐他汀治疗,通过检测平均动脉压(mAP)、平均肺动脉压(mPAP)、肺血管阻力(PVR)、心脏指数(CI)、左心室射血分数(LVER)、Borg呼吸困难指数(Borg dyspnea)、6分钟步行距离(6TWD)以及肺功能升级(WHO FC)等指标评价其疗效。结果:两组患者经过6个月的治疗后,mPAP、PVR与治疗前相比显著降低,而CI、LVEF和6MWD均显著升高,差异均有统计学意义(P<0.05),治疗前后两组mAP与Borg呼吸困难指数均没有统计学差异(P>0.05),治疗组的mAP、LVEF以及6TWD与对照组相比差异有统计学意义(P<0.05)。结论:川芎嗪联合阿托伐他汀治疗充肺动脉高压临床疗效优于单纯应用阿托伐他汀。
Objective: To observe the clinical efficacy and safety of ligustrazine plus atorvastatin in the treatment of pulmonary hypertension. Methods: Ninety-six patients with pulmonary hypertension were randomly divided into two groups, 48 in the treatment group and 48 in the control group. Patients in the treatment group were treated with ligustrazine and atorvastatin on the basis of routine treatment. Patients in the control group were treated with atorvastatin alone on the basis of conventional treatment. The mean arterial pressure (mAP), mean pulmonary arterial pressure (mPAP) (PVR), cardiac index (CI), left ventricular ejection fraction (LVER), Borg dyspnea score, 6-minute walking distance (6TWD) and lung function upgrading (WHO FC) Efficacy. Results: After 6 months of treatment, the mPAP and PVR decreased significantly compared with those before treatment, while the levels of CI, LVEF and 6MWD were significantly increased in both groups (P <0.05). Before and after treatment, There were no significant differences in the mAP and Borg indices of dyspnea between the two groups (P> 0.05). The mAP, LVEF and 6TWD in the treatment group were significantly different from those in the control group (P <0.05). CONCLUSION: TMP and atorvastatin are superior to atorvastatin in the treatment of pulmonary hypertension.